CD8A and neoplasm: Although no prospective biomarker stratification was built into the design, extensive correlative work was performed to assess: (i) PD-L1 expression on immune cells (IC2/3 by SP142 IHC), (ii) a tumor T-effector interferon-γ gene signature using the HTG EdgeSeq (Hybridization-based Targeted Gene Expression Sequencing) assay on archival FFPE tissue, and (iii) high intratumoral CD8+ T-cell density [102].